Incremental Net Benefit of Extending Human Papillomavirus Vaccine to Boys in Oropharyngeal Cancer Burden: Meta-analysis of Cost-effectiveness Studies

Overview

Journal J Dent Sci

Specialty Dentistry

Date 2024 Sep 30

PMID 39347094

Authors

Adikara Pagan Pratama

Su-Feng Chen

Shih-Chieh Liao

Wei-Chia Su

Jian-Hong Yu

Affiliations

Soon will be listed here.

Abstract

Background/purpose: The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) is increasing worldwide. HPV vaccines have shown efficacy in preventing diseases in both males and females. Therefore, there is a need to develop cost-effective strategies for HPV vaccines to prevent HPV-related OPC. This meta-analysis aimed to evaluate cost-effectiveness using the global mean of incremental cost-effectiveness ratios compared to the willingness-to-pay threshold and incremental net benefits (INBs) of HPV vaccination strategies between boys' extension vaccine and girls only. These recommendations will be useful for countries that have not implemented universal HPV vaccines in national programs, such as Taiwan.

Materials And Methods: Studies evaluating the cost-effectiveness of HPV vaccination strategies in the prevention of OPC that included both sexes versus girls only were identified through the Cochrane Library, EMBASE, PubMed, ScienceDirect, and Web of Science databases on February 05, 2024, and a meta-analysis of pooled INBs was performed using a random-effects model. The outcome was an effective measurement of the OPC burden. The results are represented in USD (2024).

Results: Fifteen model analyses were included. All the studies were conducted in high-income countries. The global mean of incremental cost-effectiveness ratio was $39,553 (95% CI, $27,008-66,641) per quality-adjusted life years gained, which was below the global mean of the willingness-to-pay threshold of $65,473 (95% CI, $52,138-83,755). Pooled INBs of $9370 (95% CI, $5046-13,695; < 0.001) favored the extended HPV in boys.

Conclusion: HPV vaccination strategies that include boys are cost-effective compared to those with girls only in preventing OPC burden. By implementing a universal HPV vaccination program, countries can receive $9370 in additional monetary benefits per patient. Given its relevance to high-income countries, this study offers key insights that can aid policymakers in Taiwan.

References

Bagepally B, Chaikledkaew U, Chaiyakunapruk N, Attia J, Thakkinstian A . Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022; 22(1):202. PMC: 8845252. DOI: 10.1186/s12913-022-07595-1. View

Simons J, Vida N, Westra T, Postma M . Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020; 38(30):4687-4694. DOI: 10.1016/j.vaccine.2020.05.031. View

Fonseca T, Jural L, Maranon-Vasquez G, Magno M, Roza A, Ferreira D . Global prevalence of human papillomavirus-related oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Clin Oral Investig. 2023; 28(1):62. DOI: 10.1007/s00784-023-05425-0. View

Ng S, Hutubessy R, Chaiyakunapruk N . Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018; 36(19):2529-2544. DOI: 10.1016/j.vaccine.2018.03.024. View

Palmer C, Tobe K, Negishi Y, You X, Chen Y, Abe M . Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan. J Med Econ. 2023; 26(1):1546-1554. DOI: 10.1080/13696998.2023.2282912. View

Ducatman B . The Role of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma. Arch Pathol Lab Med. 2018; 142(6):715-718. DOI: 10.5858/arpa.2018-0083-RA. View

Willis B, Riley R . Measuring the statistical validity of summary meta-analysis and meta-regression results for use in clinical practice. Stat Med. 2017; 36(21):3283-3301. PMC: 5575530. DOI: 10.1002/sim.7372. View

Jit M, Choi Y, Edmunds W . Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008; 337:a769. PMC: 2500202. DOI: 10.1136/bmj.a769. View

Eriksen J, Ebbesen M, Tornbjerg Eriksen K, Hjermitslev C, Knudsen C, Bertelsen P . Equity in digital healthcare - the case of Denmark. Front Public Health. 2023; 11:1225222. PMC: 10511744. DOI: 10.3389/fpubh.2023.1225222. View

10.

Linertova R, Guirado-Fuentes C, Mar-Medina J, Teljeur C . Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. Hum Vaccin Immunother. 2022; 18(6):2127983. PMC: 9746431. DOI: 10.1080/21645515.2022.2127983. View

11.

Chaturvedi A, Anderson W, Lortet-Tieulent J, Curado M, Ferlay J, Franceschi S . Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013; 31(36):4550-9. PMC: 3865341. DOI: 10.1200/JCO.2013.50.3870. View

12.

Hiles G, Chang K, Bellile E, Wang C, Yen W, Goudsmit C . Understanding the impact of high-risk human papillomavirus on oropharyngeal squamous cell carcinomas in Taiwan: A retrospective cohort study. PLoS One. 2021; 16(4):e0250530. PMC: 8064583. DOI: 10.1371/journal.pone.0250530. View

13.

Wolff E, Elfstrom K, Cange H, Larsson S, Englund H, Sparen P . Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Vaccine. 2018; 36(34):5160-5165. DOI: 10.1016/j.vaccine.2018.07.018. View

14.

Linertova R, Guirado-Fuentes C, Mar Medina J, Imaz-Iglesia I, Rodriguez-Rodriguez L, Carmona-Rodriguez M . Cost-effectiveness of extending the HPV vaccination to boys: a systematic review. J Epidemiol Community Health. 2021; 75(9):910-916. DOI: 10.1136/jech-2020-216305. View

15.

Chesson H, Ekwueme D, Saraiya M, Dunne E, Markowitz L . The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011; 29(46):8443-50. DOI: 10.1016/j.vaccine.2011.07.096. View

16.

Laprise J, Drolet M, Boily M, Jit M, Sauvageau C, Franco E . Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014; 32(44):5845-53. DOI: 10.1016/j.vaccine.2014.07.099. View

17.

Burger E, Sy S, Nygard M, Kristiansen I, Kim J . Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One. 2014; 9(3):e89974. PMC: 3961226. DOI: 10.1371/journal.pone.0089974. View

18.

Higgins J . Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2008; 37(5):1158-60. DOI: 10.1093/ije/dyn204. View

19.

Anderson S, Isaac A, Jeffery C, Robinson J, Migliarese Isaac D, Korownyk C . Practices regarding human Papillomavirus counseling and vaccination in head and neck cancer: a Canadian physician questionnaire. J Otolaryngol Head Neck Surg. 2017; 46(1):61. PMC: 5658991. DOI: 10.1186/s40463-017-0237-8. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View